Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Asthma - Pipeline Insight, 2026 | 100+ Pipeline Drugs Drive Growth in Long-Acting Biologics and Strategic Licensing Opportunities

globenewswire.com
AZN AstraZeneca is mentioned as a company with a pipeline candidate (AZD-4604) in the mid-stage of development for asthma. The article does not provide specific sentiment towards the company's performance or prospects. AMGN Amgen is listed as one of the key companies covered in the asthma pipeline report, with a pipeline product (AMG691) mentioned. The article does not offer specific sentiment or performance indicators for Amgen. PFE Pfizer is mentioned as a key company in the asthma pipeline report, with a pipeline product (PF-07275315) listed. The article does not provide any specific sentiment or performance analysis for Pfizer. CLDX Celldex Therapeutics is identified as a company with a mid-stage product (CDX-622) in the asthma pipeline. The article does not offer specific sentiment or performance details for the company. AVTX Avalo Therapeutics, Inc. is listed as a key company with a pipeline candidate (AVTX-002) in the asthma pipeline. The article does not provide specific sentiment or performance analysis for the company.

Asthma - Pipeline Insight, 2026 | 100+ Pipeline Drugs Drive Growth in Long-Acting Biologics and Strategic Licensing Opportunities Dublin, Oct. 21, 2026 (GLOBE NEWSWIRE) -- "Asthma - Pipeline Insight, 2026" has been added to ResearchAndMarkets.com's offering.

This report provides a comprehensive analysis of the global asthma pipeline, covering 80+ companies and 100+ investigational drugs across clinical, preclinical and discovery stages. It evaluates active and inactive pipeline products by development phase, product type, route of administration and molecule type, offering insight into current asthma research and development trends, unmet needs and future treatment opportunities.

Asthma remains a major chronic inflammatory respiratory disorder shaped by genetic susceptibility, immune dysregulation and environmental exposure. Its underlying mechanisms involve airway inflammation, intermittent airflow obstruction and bronchial hyperresponsiveness. Type 2 inflammatory pathways, IgE production, eosinophilic activity, mast cell signaling and dysregulated leukotriene responses contribute to disease progression. Persistent inflammation may also promote airway remodeling, fibrosis, epithelial injury and irreversible deterioration in lung function.

Diagnosis typically combines characteristic intermittent symptoms with objective confirmation of variable airflow limitation. Spirometry, bronchodilator reversibility testing, bronchoprovocation, peak flow monitoring and exhaled nitric oxide assessment may support clinical evaluation. Current asthma treatment follows a stepwise strategy that can include inhaled corticosteroids, rapid-acting and long-acting bronchodilators, anticholinergics and biologic therapies targeting specific inflammatory pathways. However, patients with severe, uncontrolled or treatment-resistant disease continue to create demand for differentiated therapeutic approaches.

Asthma Pipeline Report Scope

The report includes detailed commercial and clinical assessments of investigational asthma therapies. Individual drug profiles examine mechanisms of action, clinical studies, regulatory progress, product development activities, collaborations, licensing agreements, mergers and acquisitions, funding, designations and relevant technology platforms. The analysis also reviews asthma treatment guidelines and the potential impact of emerging drugs on the future treatment landscape.

Academic institutions and pharmaceutical and biotechnology companies are investigating novel mechanisms designed to address limitations associated with existing therapies. Development programs span late-stage, mid-stage, early-stage, preclinical and discovery research, with growing emphasis on targeted antibodies, inhaled small molecules and therapies capable of addressing multiple inflammatory endotypes.

Selected Emerging Asthma Drugs

Therapeutic Assessment

The asthma pipeline assessment categorizes approximately 100+ products across Phase III, Phase II, Phase I, preclinical, discovery, discontinued and inactive stages. Generate:Biomedicines is among the companies with an asthma candidate in the most advanced development stage.

Routes of administration assessed in the report include oral, intravenous, subcutaneous, parenteral and topical delivery. Molecule types include recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymers and gene therapies. Products are also evaluated as mono, combination and mono/combination therapies.

Key Companies and Pipeline Candidates

Leading companies covered include Generate:Biomedicines, AstraZeneca, Enveda, Celldex Therapeutics, SinoMab BioScience Ltd, Anhui Palo Alto Pharmaceuticals, Inc., HUNAN MABGEEK BIOTECH CO., LTD, Chiesi Farmaceutici S.p.A., Arrowhead Pharmaceuticals, Akeso, Keymed Biosciences Co.Ltd, Jiangsu Hengrui Pharmaceuticals Co., Ltd., Pfizer, Ethris GmbH, Windward Bio, Upstream Bio Inc., Jemincare, Longbio Pharma, Kymera Therapeutics, Inc., Avalo Therapeutics, Inc., Haisco Pharmaceutical Group Co., Ltd., Innovent Biologics (Suzhou) Co. Ltd., Sanofi, Amgen and Adovate, LLC.

Key pipeline products include GB-0895, AZD-4604, ENV-294, CDX-622, SM17, PA9159, MG-ZG122, CHF-6001, ARO-RAGE, AK139, CM512, SHR-4597, PF-07275315, ETH-47, WIN-378, Verekitug, JYB-1904, LP-003, KT-621, AVTX-002, HSK-31858, IBI3002, SAR-443765, AMG691 and ADO-5030.

Strategic Insights

The report examines clinical trial activity, emerging drug classes, novel technologies and regulatory designations across the asthma pipeline. It also assesses Industry-Industry and Industry-Academia collaborations, licensing transactions, mergers and acquisitions, and other strategic developments influencing asthma therapeutics. The findings support stakeholders seeking to evaluate competitive positioning, development risks, unmet medical needs and growth opportunities in the global asthma treatment landscape.

Key Topics Covered:

Introduction

Executive Summary

Asthma: Overview

Pipeline Therapeutics

Therapeutic Assessment

Asthma- Analytical Perspective

Late Stage Products (Phase III)

GB-0895: Generate:Biomedicines

Mid Stage Products (Phase II)

AZD-4604: AstraZeneca

Mid Stage Products (Phase I)

CDX-622: Celldex Therapeutics

Preclinical and Discovery Stage Products

Inactive Products

Asthma Key Companies

Asthma Key Products

Asthma- Unmet Needs

Asthma- Market Drivers and Barriers

Asthma- Future Perspectives and Conclusion

Asthma Analyst Views

Appendix

List of Tables [12]

List of Figures [12]

A selection of companies mentioned in this report includes, but is not limited to:

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/w79qa6

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.